MX2019011982A - Compuesto macrociclico y sus usos. - Google Patents

Compuesto macrociclico y sus usos.

Info

Publication number
MX2019011982A
MX2019011982A MX2019011982A MX2019011982A MX2019011982A MX 2019011982 A MX2019011982 A MX 2019011982A MX 2019011982 A MX2019011982 A MX 2019011982A MX 2019011982 A MX2019011982 A MX 2019011982A MX 2019011982 A MX2019011982 A MX 2019011982A
Authority
MX
Mexico
Prior art keywords
macrocyclic compound
pharmaceutically acceptable
compound
caf
activity
Prior art date
Application number
MX2019011982A
Other languages
English (en)
Inventor
Ito Ken
Kira Kazunobu
Kishi Yoshito
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/814,105 external-priority patent/US9938288B1/en
Application filed by Harvard College filed Critical Harvard College
Publication of MX2019011982A publication Critical patent/MX2019011982A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona el novedoso Compuesto (1) que tiene efectos de remodelación vascular tumoral y/o actividad anti-FAC (fibroblastos asociados al cáncer), o una de sus sales farmacéuticamente aceptables, opcionalmente en un portador farmacéuticamente aceptable, y sus usos médicos.
MX2019011982A 2017-04-05 2018-04-03 Compuesto macrociclico y sus usos. MX2019011982A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762482030P 2017-04-05 2017-04-05
US201762526677P 2017-06-29 2017-06-29
US201762586416P 2017-11-15 2017-11-15
US15/814,105 US9938288B1 (en) 2017-04-05 2017-11-15 Macrocyclic compound and uses thereof
PCT/US2018/025887 WO2018187331A1 (en) 2017-04-05 2018-04-03 Macrocyclic compound and uses thereof

Publications (1)

Publication Number Publication Date
MX2019011982A true MX2019011982A (es) 2019-11-08

Family

ID=63104288

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011982A MX2019011982A (es) 2017-04-05 2018-04-03 Compuesto macrociclico y sus usos.

Country Status (33)

Country Link
US (2) US11725015B2 (es)
EP (2) EP4119563A3 (es)
JP (4) JP6366873B1 (es)
KR (2) KR20240023674A (es)
CN (2) CN110831946B (es)
AU (2) AU2018250147B2 (es)
BR (1) BR112019020208A2 (es)
CA (1) CA3056945A1 (es)
CL (1) CL2019002854A1 (es)
CO (1) CO2019011538A2 (es)
DK (1) DK3606928T3 (es)
EC (1) ECSP19075677A (es)
ES (1) ES2931533T3 (es)
HR (1) HRP20221385T1 (es)
HU (1) HUE060466T2 (es)
IL (2) IL288991B2 (es)
JO (1) JOP20190234B1 (es)
LT (1) LT3606928T (es)
MA (1) MA48027B1 (es)
MD (1) MD3606928T2 (es)
MX (1) MX2019011982A (es)
PE (1) PE20200602A1 (es)
PH (1) PH12019502197A1 (es)
PL (1) PL3606928T3 (es)
PT (1) PT3606928T (es)
RS (1) RS63755B1 (es)
SA (1) SA519410259B1 (es)
SG (1) SG11201908603PA (es)
SI (1) SI3606928T1 (es)
TW (3) TWI836643B (es)
UA (1) UA124399C2 (es)
WO (1) WO2018187331A1 (es)
ZA (1) ZA201906279B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10556910B2 (en) 2014-06-30 2020-02-11 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
PL3606928T3 (pl) * 2017-04-05 2023-02-06 President And Fellows Of Harvard College Związek makrocykliczny i jego zastosowania
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
BR112020000141A2 (pt) * 2017-07-06 2020-07-14 President And Fellows Of Harvard College síntese de halicondrinas
CN117924310A (zh) * 2017-11-15 2024-04-26 哈佛大学的校长及成员们 大环化合物及其用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK187280A (da) 1980-04-30 1981-10-31 Novo Industri As Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
US5436238A (en) * 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
DE4229425A1 (de) 1992-09-03 1994-03-10 Kodak Ag Vorrichtung zum stapelweisen Ablegen und Ausrichten von einzeln zugeführten Blättern
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
US5352804A (en) * 1993-01-19 1994-10-04 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 2
JP2818381B2 (ja) 1994-01-18 1998-10-30 帝人株式会社 ７−チアプロスタグランジン類およびその製造法
WO1999065894A1 (en) 1998-06-17 1999-12-23 Eisai Co., Ltd. Macrocyclic analogs and methods of their use and preparation
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
JP2001305734A (ja) 2000-04-20 2001-11-02 Fuji Photo Film Co Ltd 光重合性組成物
JP2003261447A (ja) 2002-03-07 2003-09-16 Kyosei Seiyaku Kk 抗腫瘍剤
USRE46965E1 (en) 2004-06-03 2018-07-24 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of Halichondrin B
EP1831697A4 (en) 2004-12-09 2011-01-26 Eisai R&D Man Co Ltd SCREENING OF TUBULIN ISOTYPE IN CANCER THERAPY USING ANALOGUES OF HALICHONDRIN B
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
JP4910052B2 (ja) 2007-03-07 2012-04-04 インターデイジタル テクノロジー コーポレーション ＭＡＣ−ｅｈｓプロトコル・データ・ユニットを生成および処理するための方法および装置
JP2010530437A (ja) 2007-06-18 2010-09-09 メディミューン，エルエルシー ＥｐｈＡ２およびＥｒｂＢ２を発現する細胞の相乗的治療
BRPI0817909B1 (pt) 2007-10-03 2022-06-21 Eisai R&D Management Co., Ltd Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos
EP2220094A1 (en) 2007-11-16 2010-08-25 Eisai R&D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
SG189739A1 (en) 2008-04-04 2013-05-31 Eisai R&D Man Co Ltd Halichondrin b analogs
US8203010B2 (en) 2010-01-26 2012-06-19 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs
CA2824154A1 (en) 2011-01-10 2012-07-19 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
WO2013086634A1 (en) 2011-12-16 2013-06-20 Alphora Research Inc. Process for preparation of 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl) propanol derivatives and intermediates useful thereof
AU2012363334B2 (en) 2011-12-29 2017-02-02 Alphora Research Inc. 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl) tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation
IN2014MN02106A (es) 2012-03-30 2015-09-11 Alphora Res Inc
WO2014082286A1 (en) * 2012-11-30 2014-06-05 Hangzhou Zylox Pharma Co., Ltd. Rafamycin analogs and methods for making same
CA2909209A1 (en) 2013-05-15 2014-11-20 Alphora Research Inc. 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
US9850254B2 (en) 2013-07-03 2017-12-26 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing-SO2-(p-tolyl) groups
US9783549B2 (en) 2013-11-04 2017-10-10 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B
US9303039B2 (en) 2013-12-06 2016-04-05 Eisai R&D Management Co., Ltd. Methods useful in the synthesis of halichondrin B analogs
US10556910B2 (en) 2014-06-30 2020-02-11 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
US10208058B2 (en) 2014-09-09 2019-02-19 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
MX2021002629A (es) 2015-05-07 2022-05-13 Eisai R&D Man Co Ltd Reacciones de macrociclizacion e intermediarios y otros fragmentos utiles en la sintesis de macrolidos de halicondrina.
CN114272389B (zh) 2016-03-02 2023-04-18 卫材研究发展管理有限公司 基于艾日布林的抗体-药物偶联物和使用方法
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
PE20200149A1 (es) 2017-02-20 2020-01-17 Polyphor Ag Combinaciones farmaceuticas para tratar cancer
PL3606928T3 (pl) 2017-04-05 2023-02-06 President And Fellows Of Harvard College Związek makrocykliczny i jego zastosowania
US9938288B1 (en) * 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
WO2019009956A1 (en) 2017-07-06 2019-01-10 President And Fellows Of Harvard College SUMMARY OF MEDIUM MEDIATED KETONE
BR112020000141A2 (pt) 2017-07-06 2020-07-14 President And Fellows Of Harvard College síntese de halicondrinas
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
CN117924310A (zh) 2017-11-15 2024-04-26 哈佛大学的校长及成员们 大环化合物及其用途

Also Published As

Publication number Publication date
MD3606928T2 (ro) 2022-12-31
PT3606928T (pt) 2022-12-05
EP3606928A1 (en) 2020-02-12
LT3606928T (lt) 2022-12-12
JP7400025B2 (ja) 2023-12-18
BR112019020208A2 (pt) 2020-04-22
TWI781163B (zh) 2022-10-21
SG11201908603PA (en) 2019-10-30
ZA201906279B (en) 2021-01-27
HUE060466T2 (hu) 2023-03-28
JOP20190234B1 (ar) 2023-09-17
WO2018187331A8 (en) 2018-12-06
WO2018187331A1 (en) 2018-10-11
PE20200602A1 (es) 2020-03-10
IL288991A (en) 2022-02-01
CN110831946A (zh) 2020-02-21
ES2931533T3 (es) 2022-12-30
JP6366873B1 (ja) 2018-08-08
HRP20221385T1 (hr) 2023-01-06
JOP20190234A1 (ar) 2019-10-03
AU2018250147B2 (en) 2022-09-29
AU2022291454B2 (en) 2024-03-28
RU2019135531A (ru) 2021-05-05
IL288991B1 (en) 2023-08-01
JP2020513021A (ja) 2020-04-30
IL288991B2 (en) 2023-12-01
US11725015B2 (en) 2023-08-15
CL2019002854A1 (es) 2019-12-27
UA124399C2 (uk) 2021-09-08
AU2022291454A1 (en) 2023-02-16
JP2022153392A (ja) 2022-10-12
IL269788B (en) 2022-01-01
TW202426457A (zh) 2024-07-01
CN115093429A (zh) 2022-09-23
TWI836643B (zh) 2024-03-21
DK3606928T3 (da) 2022-11-28
JP2018177774A (ja) 2018-11-15
JP2024028872A (ja) 2024-03-05
EP4119563A2 (en) 2023-01-18
US20230406863A1 (en) 2023-12-21
JP7168580B2 (ja) 2022-11-09
CN110831946B (zh) 2022-06-21
TW201902902A (zh) 2019-01-16
KR20190137121A (ko) 2019-12-10
SA519410259B1 (ar) 2022-09-11
CO2019011538A2 (es) 2020-02-28
AU2018250147A1 (en) 2019-10-03
EP3606928B1 (en) 2022-09-07
EP4119563A3 (en) 2023-04-05
CA3056945A1 (en) 2018-10-11
MA48027B1 (fr) 2022-12-30
TW202321259A (zh) 2023-06-01
CN115093429B (zh) 2024-08-30
PL3606928T3 (pl) 2023-02-06
ECSP19075677A (es) 2020-01-31
RU2019135531A3 (es) 2021-09-07
SI3606928T1 (sl) 2023-02-28
KR102634732B1 (ko) 2024-02-13
US20210261566A1 (en) 2021-08-26
RS63755B1 (sr) 2022-12-30
KR20240023674A (ko) 2024-02-22
PH12019502197A1 (en) 2020-12-07
IL269788A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
PH12019502197A1 (en) Macrocyclic compound and uses thereof
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
MX2019003938A (es) Compuestos espirociclicos.
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
WO2019099646A8 (en) Macrocyclic compounds and uses thereof
TW201613887A (en) Antiproliferative compounds and methods of use thereof
NZ754865A (en) Combination therapy for the treatment of cancer
NZ745349A (en) Urea compound, preparation method therefor and medical use thereof
MX2021006901A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
IL276952A (en) History of 4,2-diaminoquinazolines and their medicinal uses
TN2019000211A1 (en) Antitumoral compounds
IL290177A (en) History of 4,2,1-oxadiazol-5-one for cancer therapy
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
PH12017500881B1 (en) Aurora a kinase inhibitor
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
WO2016130581A8 (en) Combination cancer therapy
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
MX2019002947A (es) Combinaciones que incluyen abx196 para el tratamiento de cancer.
MX2020000118A (es) Composiciones y metodos para mejorar la funcion cardiaca.
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
MX2019005504A (es) Potenciadores de bmp.
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
MX2022007630A (es) Combinaciones.
GB201907204D0 (en) Cancer treatment 3